PROGLYCEM (diazoxide)
VASODILATORS·INSULINOMA·+2
Teva Pharmaceuticals USA
Indication
Hyperinsulinism
Hyperinsulinism is an endocrine disorder characterized by excessive or inappropriate secretion of insulin by pancreatic beta cells relative to circulating glucose concentrations. Read more about Hyperinsulinism
3 drugs 3 manufacturers
Drugs that treat it
Common Hyperinsulinism therapies.
Filter & compare in the drug finder →Opens the drug finder with Hyperinsulinism preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHyperinsulinism is an endocrine disorder characterized by excessive or inappropriate secretion of insulin by pancreatic beta cells relative to circulating glucose concentrations.
While it can present across any age group due to secondary etiologies like insulinomas or severe insulin resistance, it most critically affects neonates and infants as congenital or perinatal forms.
Pathophysiologically, uninhibited insulin secretion drives systemic glucose uptake while simultaneously suppressing lipolysis and ketogenesis, leading to severe, recurrent hypoketotic hypoglycemia.
This absence of alternative cerebral fuels places affected individuals at high risk for lethargy, seizures, and irreversible neurodevelopmental damage.
- nih.gov
Hyperinsulinism is an endocrine disorder characterized by excessive or inappropriate secretion of insulin by pancreatic beta cells relative to circulating glucose concentrations
- nih.gov
Hyperinsulinism is an endocrine disorder characterized by excessive or inappropriate secretion of insulin by pancreatic beta cells relative to circulating glucose concentrations While it can present across any age group due to secondary etiologies like insulinomas or severe insulin resistance, it most critically affects neonates and infants as congenital or perinatal forms
- nih.gov
Hyperinsulinism is an endocrine disorder characterized by excessive or inappropriate secretion of insulin by pancreatic beta cells relative to circulating glucose concentrations Pathophysiologically, uninhibited insulin secretion drives systemic glucose uptake while simultaneously suppressing lipolysis and ketogenesis, leading to severe, recurrent hypoketotic hypoglycemia This absence of alternative cerebral fuels places affected individuals at high risk for lethargy, seizures, and irreversible ...
- nih.gov
While it can present across any age group due to secondary etiologies like insulinomas or severe insulin resistance, it most critically affects neonates and infants as congenital or perinatal forms
- nih.gov
While it can present across any age group due to secondary etiologies like insulinomas or severe insulin resistance, it most critically affects neonates and infants as congenital or perinatal forms Pathophysiologically, uninhibited insulin secretion drives systemic glucose uptake while simultaneously suppressing lipolysis and ketogenesis, leading to severe, recurrent hypoketotic hypoglycemia
- nih.gov
Pathophysiologically, uninhibited insulin secretion drives systemic glucose uptake while simultaneously suppressing lipolysis and ketogenesis, leading to severe, recurrent hypoketotic hypoglycemia
- medlineplus.gov
This absence of alternative cerebral fuels places affected individuals at high risk for lethargy, seizures, and irreversible neurodevelopmental damage
- nih.gov
This absence of alternative cerebral fuels places affected individuals at high risk for lethargy, seizures, and irreversible neurodevelopmental damage
Personalize your experience
Follow Hyperinsulinism and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.